Trial Profile
Estimation of outcome by FRET Analysis for Newly diagnosed CML-CP patients treated with Tasigna
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2020
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms EsoFANTA
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 Mar 2012 New trial record